NicoTest is a point of care diagnostic kit that enables healthcare professionals to help smokers to achieve a significantly higher success rate in smoking cessation.  The results allow the user to identify which drug treatment is most likely to work best for that individual and advice on the optimum dosing level for nicotine replacement (if that is the preferred course of treatment). This intervention considerably improves drug-safety profiles over conventional methods and financial savings and clinical benefits accrue to those who pay for treatment. UK authorities are presently reviewing our clinical data and we anticipate will augment their existing guidelines to include it within existing protocols and ultimately reimburse it.

The introduction of NicoTest has given us insights to the developing Personalised Treatment market enabling us to design and construct a Companion Diagnostic delivery platform that is applicable across a wide range of therapeutic sectors

NicAlert™ is used to validate smoking cessation or exposure and is the ONLY accurate, CE Marked, Point of Care test for use by Healthcare Professionals to identify and distinguish between smokers and non-smokers.

NicAlert™ is a simple point of care diagnostic test that:

• Is a FDA and CE approved
• Can be used either with a urine or a Saliva sample
• Test for cotinine (a nicotine metabolite) in 20 minutes
• Is a cost-effective semi-quantative test to determine smoking status
• Is a fast, inexpensive and easy to use disposable test strip
• Visit the NicAlert website here .

For enquiries please contact:

• Tel: +44 (0)870-770-2850
• Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Please contact us to discuss discounts for R&D Applications of NicAlert™

R&D

We are actively involved in a number of R&D programmes and anticipate making further Personalised Treatment programmes available in the future with our partners. If you are interested in developing a commercial route to market for your Pgt biomarker please feel free to contact us for a confidential discussion.